NOX and US Govt Peak Cancer Agency Announce Collaboration  
 
    NOX Announces AU$26 Million Funding Facility  
 
    Conference Hears of Positive Interim Data from LuPIN Trial  
 
    Noxopharm Corporate Presentation June 2019  
 
    DARRT-1 Study Fully Enrolled  
 
    Promising Data Leads to Expansion of LuPIN Trial  
 
    LuPIN Trial Demonstrates High Rates of Response  
 
    DARRT Treatment Has Lasting Disease Control at Six Months  
 
    Veyonda and Immuno-Oncology Effect Explained  
 
    Change in Noxopharm Limited Board Structure  
 
    Idronoxil Confirmed as New Immuno-Oncology Drug  
 
    Veyonda Chemotherapy Enhancement Program to be Expanded  
 
    Noxopharm to expedite Veyonda Clinical Program  
 
    FNN interview with Nox Chief Medical Officer on Interim Data  
 
    Chief Medical Officer Discusses DARRT-1 trial interim results  
 
    Veyonda and Radiotherapy Delivers Clinical Benefits  
 
    Appendix 4C - quarterly report for the quarter ended December 31, 2018  
 
    DARRT-1 study advancing on basis of positive clinical data  
 
    NOX announces Positive Data from CEP-1 Study of Veyonda  
 
    NOX 2018 AGM Presentations  
 
    NOX to Present Clinical Data at COSA Annual Meeting  
 
    Corporate Presentation  
 
    NOX makes key executive appointment  
 
    Noxopharm Releases Report on Key Progress of Subsidiary  
 
    Annual Report to shareholders  
 
    NOX Subsidiary Announces Important Drug Discovery  
 
    NOX to support expanded LuPIN study  
 
    Nyrada-Key progress with cholesterol-lowering drug candidate  
 
    VEYONDA - Registered Trade Mark for NOX66  
 
    Interim NOX66 Radiotherapy Clinical Data  
 
    Release of DARRT-1 Preliminary Safety Data  
 
    Pre-Clinical data confirms Radio-Enhancing potential  
 
    Noxopharm Corporate Presentation for Public Briefing  
 
    End-of-Study Clinical Data shows benefit of NOX66  
 
    NOX to present at American Society of Clinical Oncology  
 
    Noxopharm 2018 Mid-Year Investor Briefings  
 
    NOX CEO interview updates the company's current R&D program  
 
    NOX CEO interview on near complete NOX66 chemotherapy trial  
 
    NOX CEO interview on Radiotherapy Clinical Programs  
 
    St Vincent's Hospital study passes first milestone  
 
    DARRT-1 Clinical Study commences  
 
    NOX raises $10.8 M to advance clinical program  
 
    Evidence of Abscopal Responses in Patients  
 
    Corporate Presentation - Post Interim Clinical Data Release  
 
    FNN Interview with Noxopharm CEO  
 
    NOX Reports NOX66 Clinical Data  
 
    NOX closes $4m capital raising for US subsidiary Nyrada Inc  
 
    NOX receives FY17 R&D Tax Rebate  
 
    EOY Guidance on 2018 NOX66 Clinical Development Strategy  
 
    NOX Open Briefing Corporate Presentation  
 
    Compassionate use of NOX66 in Patients  
 
    AGM Presentations  
 
    Promising Interim Clinical Data for NOX66  
 
    Results of Meeting  
 
    EGM Presentations  
 
    UNSW collaboration confirms drug designed for stroke victims  
 
    Appendix 4C - quarterly  
 
    Update - General Meeting Agenda  
 
    October 2017 Open Briefing Corporate Presentation  
 
    Australian NOX66 - Radiotherapy Study Opens  
 
    Establishment of Nyrada Inc.  
 
    Positive Clinical Outcomes for NOX66 at ESMO Conference  
 
    NOX CEO Interview explains recent Brain Cancer Announcement  
 
    Important Brain Cancer Findings for NOX66 Program  
 
    Reinstatement to Official Quotation  
 
    Noxopharm raises $5.5 million to advance clinical program  
 
    Suspension from Official Quotation  
 
    Trading Halt Request  
 
    Trading Halt  
 
    NOX Corporate Presentation ahead of Conference  
 
    Noxopharm's first 12 months since ASX listing  
 
    NOX Research Report prepared by APP Securities  
 
    CEO Interview with FNN - Singapore and HK Roadshow  
 
    New Corporate Presentation  
 
    Noxopharm provides update on NOX66 Clinical Trial Program  
 
    Idronoxil data provides hope to treat secondary brain cancer  
 
    NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment  
 
    New Corporate Presentation  
 
    St Vincents Cancer Study to Commence-NOX66 and Radiotherapy  
 
    NOX makes strategic commitment to treatment of rare cancers  
 
    Noxopharm Mid Year Investor Briefings  
 
    Market Guidance for Next Six Months  
 
    Appendix 4C - quarterly  
 
    FNN Interview with NOX CEO Explaining Idronoxil-C Discovery  
 
    NOX Files Patent Application on 'Smart' Idronoxil  
 
    NOX and Monash Uni Collaboration Receives Federal Grant  
 
    Noxopharm and UNSW combine on stroke project  
 
    Gold Coast Qld Mid-Year Briefing Details  
 
    NOX researching rare Abscopal Response  
 
    Upcoming Events and Presentations  
 
    February 2017 Newsletter  
 
    Noxopharm CEO to present at ASX The CEO Sessions  
 
    Breakthrough in Delivering Idronoxil into Brain  
 
    Corporate Presentation Updated  
 
    Corporate Presentation Providing Clinical Program Guidance  
 
    Medical Advisors Appointed for Extensive Clinical Program  
 
    Independent Investment Research Report November 2016  
 
    Corporate Presentation  
 
    APP Securities Company Research Report September 2016  
 
    Noxopharm Limited Closes Oversubscribed IPO  
 
    Noxopharm Press Release